Anteo Diagnostics Acquires DIAsource ImmunoAssays SA

BBI Group Acquires DIARECT AG

June 3, 2020

Medical Devices

BBI Group has acquired DIARECT AG, a Freiburg-based supplier of recombinant autoimmune antigen products, integrating DIARECT's manufacturing facility to establish a centre of excellence for recombinant antigen development. The deal expands BBI's immunoassay reagent portfolio and capabilities, enabling the combined company to pursue high-growth disease segments and broaden DIARECT's geographic reach through BBI's larger sales organization.

Fremman Capital Acquires Majority Stake in DIESSE Diagnostica Senese

January 27, 2025

Medical Devices

Fremman Capital has acquired a majority stake in Italian In Vitro Diagnostics (IVD) company DIESSE Diagnostica Senese from ARCHIMED's MED II. DIESSE, headquartered in Monteriggioni (Siena), Italy, operates a new biotech campus and ~230 employees and will continue to be led by its management team which retains a meaningful minority stake; Fremman plans to further internationalize and grow the business.

ARCHIMED (via Duomodiag) Acquires DIESSE Diagnostica Senese SpA

May 13, 2019

Medical Devices

ARCHIMED, through its MED II-backed holding company Duomodiag Sarl, acquired Italian in vitro diagnostics specialist DIESSE Diagnostica Senese SpA in a cross-border carve-out completed on May 13, 2019. The deal — financed by MPS Capital Services and BPER — purchased DIESSE from its founders and Orphée SA (the Swiss subsidiary of the PZ Cormay group) to accelerate product innovation and expand market penetration internationally.

bioMérieux Acquires Specific Diagnostics

April 12, 2022

Medical Devices

bioMérieux has agreed to acquire Specific Diagnostics, a U.S.-based developer of the SPECIFIC REVEAL Rapid AST system, to strengthen its sepsis and antimicrobial stewardship portfolio. bioMérieux will acquire 100% of Specific Diagnostics for a consideration equivalent to 3.3% of bioMérieux's market capitalization as of April 11, 2022, paid in cash and newly issued shares; the deal was expected to close by the end of Q2 2022 subject to regulatory approvals.

Biosynth Carbosynth Acquires Aalto Bio Reagents

May 26, 2022

Biotechnology

Biosynth Carbosynth, a Swiss life‑sciences supplier, has acquired Aalto Bio Reagents, a Dublin‑based developer and provider of biological materials for in‑vitro diagnostics (IVD) and vaccine development. The deal strengthens Biosynth’s IVD and vaccine product portfolio and expands its capabilities to serve diagnostics and vaccine development customers worldwide.

Sebia Acquires ORGENTEC Diagnostika from Water Street Healthcare Partners

June 30, 2021

Medical Devices

Sebia, a France-based provider of clinical protein electrophoresis systems, agreed to acquire ORGENTEC Diagnostika (including subsidiaries Corgenix and AROTEC) from Water Street Healthcare Partners. The acquisition expands Sebia's capabilities and product portfolio in autoimmune and infectious-disease diagnostics, clinical trials support, and global commercial reach.